Gilead Sciences researches, develops, and commercializes antiviral and other specialty medicines. The company is a leader in HIV treatment and has developed curative therapies for hepatitis C as well as products in oncology and inflammation. Its medicines are distributed globally through partnerships and direct commercialization in key markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 7,081 | — | 1,960 | -21.7% |
| Q3 2025 | 7,769 | — | 3,052 | 21.4% |
| Q4 2025 | 7,924 | — | 2,183 | -7.8% |
| Q1 2026 | 6,960 | — | 2,021 | -10.4% |
| Q2 2026 | 7,803 | 10.2% | -10,496 | -635.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Analog Devices, Inc. (ADI), Sandisk Corporation (SNDK), QUALCOMM Incorporated (QCOM), PepsiCo, Inc. (PEP), T-Mobile US, Inc. (TMUS), Intuitive Surgical, Inc. (ISRG)